Home > Treatment Options > Tumor Suppressors > Clinical Trials >
Hydroxycarbamide
Last Updated: 03/28/17
Status: Determined Ineffective for NF2
Index
- Trials
- Other Uses
Hydroxycarbamide, is no longer used or recommended for the treatment of NF2.
| Other Names | Hydroxyurea, Hydroxycarbamide, Hydrea, N-Hydroxyurea, Litalir, Oxyurea, Onco-carbide, Biosupressin, Droxia, Hidrix |
|---|---|
| Trade Name | Hydrea™ Droxia™, Apo-Hydroxyurea™ and Gen-Hydroxyurea™, |
| Treatment By | Pill - Oral |
| Inhibitor | An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. |
| Molecular Formula | CH4N2O2 |
|---|---|
| IUPAC | hydroxyurea |
| ChemSpider | 3530 |
| PubChem | CID 3657 |
Trial
- Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG - www.ClinicalTrials.gov
- Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV) - www.ClinicalTrials.gov
- Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG - www.ClinicalTrials.gov
- Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma - www.ClinicalTrials.gov
Other Uses
- Myeloproliferative disease
- Sickle-cell disease
- AIDS
- Second line treatment for psoriasis
- Systemic mastocytosis
- Chronic myelogenous leukemia (replaced by imatinib
- Biochemical research as a DNA replication inhibitor
